Fanconi Anemia Complementation Group J C1836860
A rare genetic disorder affecting DNA repair, causing bone marrow failure and increased cancer risk. Management includes supportive care and stem cell transplant for eligible patients.
Key facts at a glance
- ICD-10
- D61.03
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Bone marrow failure (pancytopenia)
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Congenital skeletal anomalies (radial ray defects, thumb anomalies)
(hematologic)Renal malformations
(hematologic)Ocular abnormalities (microphthalmia, strabismus)
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Hematopoietic Stem Cell Transplantation
Curative approach for bone marrow failure using chemotherapy and/or radiation followed by infusion of donor stem cells. This is the definitive treatment for severe aplastic anemia in Fanconi anemia patients.
Androgen Therapy
Synthetic androgens such as oxymetholone may stimulate bone marrow production and improve blood counts. This serves as a bridge therapy while awaiting transplantation or for patients without a suitable donor.
Additional treatment options
Hematologic Monitoring Program
Frequent complete blood counts and bone marrow evaluations to track disease progression and guide timing of intervention such as transplantation or supportive therapies.
monitoringNutritional Support Program
Comprehensive nutritional assessment and supplementation to address growth concerns, prevent malnutrition, and support immune function in Fanconi anemia patients with feeding difficulties or increased metabolic demands.
dietaryGrowth Factor Support
Granulocyte colony-stimulating factor (G-CSF) may be used to manage neutropenia and reduce infection risk in selected patients with appropriate monitoring.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Fanconi Anemia Complementation Group J C1836860?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Fanconi Anemia Complementation Group J C1836860. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy